Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Data Bank for Rheumatic Diseases (NDB) | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Observational registry to assess the longer-term risk of serious infections and malignancies reported with TNFα-blocker therapy, as well as the longer-term risk of cardiovascular and thromboembolic events in adult Rheumatoid Arthritis (RA) patients treated with Cimzia® as compared to non-biologic DMARD-treated controls.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Certolizumab pegol (CZP) | Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®) | ||
| Non-biologic DMARD | Subjects with RA receiving treatment with non-biologic DMARD |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with lymphoma | Number of participants with lymphoma during the observational period (up to 6 years) | 6 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with serious infections | Number of participants with serious infections during the observational period (up to 6 years) | 6 years |
| Number of participants with non-lymphoma malignancies |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Rheumatologist referral or patient direct enrollment
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frederick Wolfe, M.D. | National Data Bank for Rheumatic Disease | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Number of participants with non-lymphoma malignancies during the observational period (up to 6 years)
| 6 years |
| Number of participants with cardiovascular events | Number of participants with cardiovascular events during the observational period (up to 6 years) | 6 years |
| Number of participants with thromboembolic events | Number of participants with thromboembolic events during the observational period (up to 6 years) | 6 years |
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided